Status:
NOT_YET_RECRUITING
Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Hematological Malignancies
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option for many hematological maligancies. The main cause of death following HSCT is the relapse of the original disease...
Eligibility Criteria
Inclusion
- Patient \> 18y/o
- Patient who received an allogeneic stem cell transplantation for an acute myeloid leukemia and who will receive gilteritinib as post transplantation maintenance
- Matched related, matched unrelated, mismatched unrelated and haploidentical donors
Exclusion
- Minors
- Pregnant women
- Patient under 'tutelle', 'curatelle' or in prison
- Patient who has been treated for a solid tumor in the past 2 years
- Known human immunodeficiency virus (HIV) infection or HIV-related malignancy
- Clinically active hepatitis B or hepatitis C infection
- Known allergy or hypersensitivity to gilteritinib
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06992934
Start Date
August 1 2025
End Date
August 1 2028
Last Update
August 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de NICE
Nice, France